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Abstract
Malignant pleural mesothelioma (MPM) is a highly lethal cancer of the lining of the chest cavity. 
To expand our understanding of MPM, we conducted a comprehensive integrated genomic study, 
including the most detailed analysis of BAP1 alterations to date. We identified histology-
independent molecular prognostic subsets, and defined a novel genomic subtype with TP53 and 
SETDB1 mutations and extensive loss of heterozygosity. We also report strong expression of the 
immune checkpoint gene VISTA in epithelioid MPM, strikingly higher than in other solid cancers, 
with implications for the immune response to MPM and for its immunotherapy. Our findings 
highlight new avenues for further investigation of MPM biology and novel therapeutic options.
Keywords
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Introduction
Malignant pleural mesothelioma (MPM) is a cancer of the mesothelial cells lining the 
pleural cavity. It was rare until the widespread use of asbestos in the mid-20th century (1). 
Although reduction and strict regulation of asbestos use may be leading to a leveling off in 
new cases in Western countries, its long latency, together with continued use of asbestos in 
non-Western countries, ensures that MPM remains a global problem (2). MPM is almost 
universally lethal, with only modest survival improvements in the past decade (3), 
suggesting that standard treatment is reaching a therapeutic plateau. Elucidating oncogenic 
genomic alterations in MPM is therefore essential for therapeutic progress (4–7). Frequent 
copy number loss and recurrent somatic mutations in BAP1, NF2, CDKN2A, and others 
have been identified (4–6), yet no targeted therapies exploiting these alterations have 
emerged.
To expand our understanding of the molecular landscape and biological subtypes of MPM, 
and provide insights that could lead to novel therapies, we have conducted a comprehensive, 
multi-platform, genomic study of 74 MPM samples, as part of The Cancer Genome Atlas 
(TCGA). Here, we report how these integrated analyses define prognostic subsets of MPM, 
characterize a new near-haploid molecular subtype, and identify novel potential therapeutic 
targets.
A detailed description of the sample acquisition and pathology review process, as well as the experimental and computational methods 
used for the different analyses presented in our study is provided as Supplementary Sections 1–13.
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We studied 74 samples of primary MPM from patients with no prior systemic therapy. This 
cohort was predominantly male (82%), with a median age of 64 years, and tumors were of 
mostly epithelioid histology (70%), a typical profile for MPM. Asbestos exposure history 
was positive in 62%, negative in 18%, and unavailable or unknown in the remainder. 
Demographic and clinical details are provided in Supplementary Tables S1A and S1B, as 
well as Supplementary Fig. S1.
We performed comprehensive molecular profiling, including exome sequencing, copy 
number arrays (Supplementary Fig. S2), mRNA sequencing (Supplementary Fig. S3), non-
coding RNA profiling, DNA methylation (Supplementary Fig. S4) and reverse-phase protein 
arrays (RPPA; Supplementary Fig. S5). Methods and detailed results of individual analyses 
are provided in Supplementary Sections 1–13.
Landscape of somatic mutations and copy number alterations
Whole exome sequencing (WES) revealed a somatic mutation rate of <2 non-synonymous 
mutations per megabase in all samples except for an outlier case with a mutation rate of 8 
non-synonymous mutations per megabase (Fig. 1A). This places MPM at the low end of 
somatic mutation burden among cancers (8). The outlier tumor with a ten-fold higher 
mutation rate showed a distinctive pattern of C>T mutations occurring almost exclusively at 
CpG dinucleotides (Fig. 1B). This relatively hypermutated tumor harbored a homozygous 
nonsense mutation in MSH2, which would suggest that the tumor lacked mismatch repair 
capacity but the observed mutational spectrum was atypical for mismatch repair deficiency 
(9). Otherwise, the observed mutational spectrum was similar across patients and lacked 
distinctive or novel features (Fig 1C). Signatures of smoking- or APOBEC-induced 
mutagenesis were not observed. Asbestos has been proposed to cause genotoxicity via DNA 
breaks and secondary oxidative damage (10). However, the mutational spectrum and local 
sequence context was not significantly different between cases with or without known 
asbestos exposure (chi-squared, P=0.3); while this negative finding should be viewed with 
caution given the limitations of the dataset, it is in agreement with prior studies (5).
We sought to identify genes mutated significantly above the background rate using 
MutSig2CV. Significantly mutated genes (SMGs) at an FDR < 0.05 included BAP1, NF2, 
TP53, LATS2 and SETD2, all known cancer genes in MPM (Fig. 1A, Supplementary Table 
S1C). All five genes showed high rates of nonsense, frameshift and splice site mutations, 
highlighting them as targets of inactivation consistent with their functions as tumor 
suppressors. Mutations in these five SMGs did not show associations with histories of 
asbestos exposure or smoking. For validation in an independent cohort that also used a 
different algorithm to define SMGs, we compared the results of our SMG analysis with the 
SMGs previously identified in 99 MPM exomes using the MUSIC algorithm (5) and found a 
strong overlap for SMGs at an FDR < 0.05 in both studies (Fig. 1D). Notably, among lower 
confidence SMGs (FDR < 0.15 but > 0.05), only SETDB1, which may define a novel 
subtype of MPM (discussed below), was identified in both analyses (Fig. 1D).
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The somatic copy number alteration (SCNA) landscape was characterized by frequent 
recurring focal and arm-level deletions, but no recurring amplifications, consistent with the 
notion that MPM development is driven primarily by loss of tumor suppressor genes, rather 
than by activation of classic oncogenic driver genes (Supplementary Section 4, Fig. S2). 
Focal deletions affected several tumor suppressor genes known to be altered in MPM (5), 
most notably CDKN2A with deletions (defined as deep, likely homozygous) in 36 (49%) 
and losses (defined as shallow, possibly single-copy) in 5 (7%) samples. Likewise, NF2 
deletions were confirmed in 25 (34%) and losses in 30 (40%) samples; as many of the latter 
harbored mutations of the remaining allele, evidence of biallelic NF2 inactivation was 
common (Fig 1A). CDKN2A deletions often encompass MTAP, the adjacent gene on 9p21 
(11), which encodes methylthioadenosine phosphorylase, whose deficiency has recently 
been reported to lead to reduced PRMT5 enzymatic activity and heightened sensitivity to its 
pharmacologic inhibition (12,13). Co-deletion of CDKN2A and MTAP, associated with low 
levels of mRNA expression of both genes, was observed in 20 cases (Supplementary Fig. 
S2). Whilst no correlation with overall survival was observed for BAP1 status, loss of 
CDKN2A was strongly associated with shorter overall survival (Cox proportional hazards, 
P=7.3×10−6), as previously shown (14,15).
Finally, an analysis for genomically-integrated viral sequences, including SV40, was 
negative (Supplementary Section 8), as was a screen of exome and RNA sequencing data for 
evidence of EWSR1 and ALK fusions, recently reported in rare cases of MPM (16,17) and 
peritoneal mesothelioma (18), respectively. As well, no activating mutations in the canonical 
MAPK or PI3/AKT signaling pathways were identified in this cohort.
Comprehensive analysis of BAP1 status in MPM
BAP1, encoding a nuclear deubiquitinase, is the most frequently mutated cancer gene in 
MPM, both in our dataset and others (5), and is also recurrently inactivated in clear cell renal 
carcinoma, uveal melanoma, and cholangiocarcinoma (19). Somatic BAP1 mutations have 
germline counterparts that define the BAP1 hereditary cancer syndrome (20). In contrast to 
other cancers, BAP1 inactivation in MPM does not correlate with adverse outcomes. 
Because its role in MPM biology remains unclear, we compared BAP1 inactivated and wild-
type cases across multiple platforms. First, to better segregate cases according to BAP1 
status, we performed a comprehensive analysis of inactivating alterations through a detailed 
review of SNVs, small and large indels, whole gene deletions, and structural variants; this 
showed the overall prevalence of BAP1 alterations to be 57% (Fig. 1A, Supplementary Table 
S2A), in line with recent studies (21). Most MPM with inactivating mutations in BAP1 
(25/26, 96%) also had concurrent loss of heterozygosity on chromosome 3p21.1, supporting 
a classic two-hit tumor suppressor mechanism. Overall, BAP1 status was defined as follows: 
32 samples with no evidence of BAP1 alteration, 6 with a single (heterozygous) mutation or 
deletion and 36 with biallelic inactivation. No germline mutations in BAP1 were identified 
in this cohort.
BAP1 alterations showed non-random patterns of co-occurrence with mutations in other key 
MPM cancer genes (Fig. 2A). As expected, mRNA expression levels of BAP1 itself were 
reduced in the presence of genomic BAP1 inactivation or loss (Fig 2B). We also observed an 
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inverse correlation of BAP1 alterations and SCNAs. BAP1-altered tumors had fewer 
chromosome arm gains and losses (Fig. 2C, median 9.5 vs. 15.5, Mann-Whitney, P<0.01), as 
well as fewer focal SCNAs (Supplementary Fig. S2).
Since BAP1-mediated deubiquitination of histones and transcriptional proteins is thought to 
regulate gene expression, we compared mRNA expression patterns between tumors that 
were wild-type for BAP1 and those with inactivation of one or both BAP1 alleles. We 
identified 1,324 differentially expressed genes with a FDR <0.01, of which 75% were 
downregulated in the BAP1-inactivated samples. As previously noted in experimental 
models (22), BAP1-inactivated tumors in our cohort had lower mRNA expression of several 
HOXA genes, including HOXA5 and HOXA6, but no difference in EZH2 mRNA expression 
or its PRC2 partners EED and SUZ12.
As BAP1 is known to regulate the ubiquitination and hence stability of several 
transcriptional proteins, we examined the association of BAP1 status with inferred activity 
of transcription factors (TF) using a recently developed computational strategy that 
integrates phosphoproteomic and transcriptomic data with predicted transcription factor 
binding sites (23). We used this algorithm to assess significant differences in inferred TF 
activities between BAP1-inactivated and wild-type MPM (satisfying FDR-corrected P<0.01, 
t-test), linking BAP1 status to altered activity of TFs. Indeed, many TFs identified in this 
analysis had highly significant associations with BAP1 status (Fig. 2D and 2E; 
Supplementary Table S2B).
In particular, YY1 had a significantly reduced inferred activity in BAP1-inactivated samples 
(Fig 2F). BAP1 forms a ternary complex with HCF1 and YY1, which acts as transcriptional 
repressor of genes involved in cell proliferation (24). YY1 has also been shown to regulate 
or interact with other TFs whose inferred activity was also altered in our analysis, such as 
MAX and EGR2. Moreover, there is evidence that YY1 interacts with EZH2, the catalytic 
subunit of PRC2, and is required for its function in gene silencing (25). Thus, to a degree, 
the transcriptional consequences of BAP1 inactivation could be attributed to changes in 
recruitment of specific TFs to their target genes, either directly, as in the loss of ternary 
YY1-HCF1-BAP1 complexes, or indirectly, as in the case of TFs that are themselves 
downstream targets of YY1 (Supplementary Table S2C).
Notably, BAP1-inactivated samples demonstrated a significantly increased inferred activity 
of IRF8 (Fig. 2G, Supplementary Table S2D), a hematopoietic lineage TF involved in 
interferon signaling and dendritic cell differentiation. Both pathways were upregulated in 
our BAP1-based supervised gene mRNA expression analysis (see above). Moreover, 
PARADIGM analysis confirmed that the IRF activation pathways are upregulated in BAP1-
inactivated samples. IRF8 has been implicated in the biology of CD103-positive dendritic 
cells whose antigen-presenting function is highly effective at stimulating cytotoxic T cells in 
the tumor microenvironment (26). Taken together, these observations suggest an association 
between BAP1 status and perturbed immune signaling in MPM that warrants further 
exploration.
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MPM with genomic near-haploidization, a novel subtype
Allele-specific copy number analysis of WES data using the FACETS algorithm (27) 
identified three cases with striking genome-wide LOH that affected more than 80% of the 
genome, which was confirmed in SNP6.0 copy number array data (Fig. 3A and 3B, 
Supplementary Fig. S2). This phenomenon, well-described in acute lymphoblastic leukemia 
(28), occurs when the nascent cancer clone loses one copy of nearly all chromosomes 
(which we term ‘genomic near-haploidization’, GNH) followed by duplication of the 
remaining chromosomes. To better assess the prevalence of this unusual genomic 
phenomenon in MPM, we screened 80 samples from a Japanese International Cancer 
Genome Consortium (ICGC) MPM cohort, identifying two additional cases (Fig. 3B), 
representing a combined prevalence of 5/154 (3.2%). Neither the three TCGA cases, nor the 
two ICGC cases, had deletions or point mutations in BAP1, PBRM1 or SETD2. 
Remarkably, all 5 cases had inactivating point mutations in, or homozygous deletion of, 
SETDB1, which encodes a histone methyltransferase involved in gene silencing, 
representing the only SETDB1-mutated MPMs in the combined TCGA-ICGC cohort. 
Additionally, 4 of 5 cases with evidence of GNH had driver mutations in TP53. Although 
near-haploid cases have been reported in other cancers (e.g. acute lymphoblastic leukemia, 
chondrosarcoma, adrenocortical carcinoma), the strong association of TP53 and SETDB1 
co-mutation with widespread LOH has not been previously reported in other cancers 
(28,29).
To further define the clinical features of this novel subset, we obtained data on 16 additional 
cases with near-haploid karyotypes from a large independent series of MPM studied by 
cytogenetic analysis of short-term primary cultures (Supplementary Section 2.2; Note: 
cytogenetic analysis can only identify genomic near-haploidization cases which have not 
undergone genome duplication). Although most of the genome in our 5 cases showed LOH, 
chromosomes 5 and 7 strikingly retained heterozygosity (Fig. 3C). These two chromosomes 
also remained disomic in the cases with near-haploid karyotypes in the independent 
cytogenetic series (Supplementary Table S3). Based on this combined set of 21 near-haploid 
MPM, a distinctive profile of genomic and clinical features emerged, demarcating a novel 
molecular subtype of MPM. Strikingly, most patients with MPM showing genomic near-
haploidization were female (M:F=1:4), in sharp contrast to the overall TCGA-ICGC MPM 
cohort, where males greatly predominated (M:F>4:1; p<0.01, Fisher’s exact test). No 
difference in distribution of histological types was observed in the GNH subset.
Since MPM with evidence of GNH have typically undergone a genome-doubling event, we 
were able to assess the timing of this relative to point mutations (30,31). Essentially, 
mutations acquired before genome duplication would be present on both copies of the 
duplicated chromosome, whereas those occurring after would be heterozygous. In all three 
TCGA cases with genomic near-haploidization, the majority of the point mutations were 
present on both copies of duplicated chromosomes, suggesting the genome duplication 
occurred relatively late in the evolution of the cancer. In three cases, the TP53 driver 
mutation was homozygous, suggesting it occurred before genome doubling. In contrast, the 
SETDB1 mutations were present on only one of the two copies of chromosome 1 in two of 
the three cases, suggesting they occurred after LOH and genome duplication (Fig. 3D). 
Hmeljak et al. Page 6













Overall, these data suggest a model in which TP53 mutations occur early, and presumably 
permit the steady (or catastrophic) loss of chromosomes. It seems likely that genome 
reduplication occurs after achieving near-haploidy, with haploinsufficiency of SETDB1 
arising later.
Integrative Multi-Platform Analysis Defines Novel Prognostic Subsets
While the current classification of MPM into epithelioid, sarcomatoid and biphasic 
histologies is prognostically useful, there remains variability in clinical features and patient 
outcomes within histological subtypes. Previous analyses (5,7) based on mRNA expression 
alone have defined unsupervised clusters largely recapitulating these histologic distinctions. 
To find out whether multi-platform molecular profiling might provide additional resolution 
to define prognostic subsets of MPM, we performed integrative clustering across multiple 
assay platforms using two algorithms: iCluster (32) and PARADIGM (33). Both identified 
four distinct integrated subtypes of MPM. There was a strong concordance in subtype 
assignments between the two algorithms (Fig. 4A, Supplementary Figs. S6, S7), especially 
for the best (cluster 1) and worst (cluster 4) prognosis clusters, indicating that integration of 
molecular data can identify distinct subgroups of MPM, independent of the specific 
statistical methodology. Survival was significantly different across the 4 clusters (P<0.0001 
for either algorithm; Fig. 4B, Supplementary Fig. S7). This survival difference remained 
significant (P=0.008) after adjusting for histology (epithelioid vs. non-epithelioid) and 
CDKN2A homozygous deletion (Fig. 4C, Supplementary Fig. S6), a known molecular 
prognostic factor in MPM (14,15). While they did provide additional independent prognostic 
information, the iClusters nonetheless did show correlation with consensus histology 
(p=0.002), with iCluster cluster 1 being enriched for epithelioid histology (similar finding 
for Paradigm cluster 1). They also exhibited differences in immune cell infiltrates 
(Supplementary Table S4A), as discussed below, but showed no significant correlation with 
clinical variables such as T stage, N stage, asbestos exposure history, or smoking 
(Supplementary Table S4B). Molecularly, these tumors had low SCNA, relatively few 
CDKN2A homozygous deletions (11%), and a high level of methylation (Supplementary 
Fig. S4). All but one (95%) had BAP1 alterations: 26% had homozygous deletions and 53% 
had heterozygous loss with mutations.
The poor prognosis cluster (cluster 4; red) had a high score for epithelial-mesenchymal 
transition (EMT) based on gene expression (P<0.001; Figs. 4D), which was distinguished by 
high mRNA expression of VIM, PECAM1 and TGFB1, and low miR-200 family 
expression. These tumors also displayed MSLN promoter methylation and consequent low 
mRNA expression of mesothelin, a marker of differentiated mesothelial cells, as noted 
previously in sarcomatoid MPM and the sarcomatoid components of biphasic MPM (15,34). 
Overall, this poor prognosis cluster also showed enrichment of LATS2 mutations (30% 
compared to 4% in the rest of the cohort) and CDKN2A homozygous deletions (66%). 
Moreover, this cluster showed higher AURKA mRNA expression, higher leukocyte fraction 
(based on methylation), and elevated mRNA expression of E2F targets, G2M checkpoints, 
and DNA damage response genes. PI3K-mTOR and RAS/MAPK signaling was upregulated, 
based on both mRNA and protein expression (Supplementary Fig. S7). Additionally, several 
miRNAs were differentially expressed between the good and poor prognostic clusters, 
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including miR-193a-3p, which has been proposed as a potential tumor suppressor (35). 
Finally, a comparison of immune gene mRNA expression signatures (36) across the four 
clusters revealed a significantly higher score for the Th2 cell signature in the poor prognosis 
Cluster 4 compared to the other clusters (Fig. 4E, Supplementary Table S4A). 
Coincidentally, it has been reported that Th2 cytokines secreted by immune cells upon 
exposure to asbestos may promote MPM (37). The analyses of other immune signatures are 
shown in Supplementary Fig. S5.
While biphasic and sarcomatoid MPM are more aggressive, there remains a need for 
improved risk stratification of epithelioid MPM, for which clinical outcomes are more 
heterogeneous. Therefore, we conducted an integrative clustering analysis restricted to 
epithelioid MPM. The results for the 4-cluster epithelioid-only solution were highly similar 
to the 4-cluster all-MPM solution (Fig. 5A), with only 7 of the 52 epithelioid samples 
reassigned to other clusters. This stability indicates that the features driving the all-MPM 
clustering are largely independent of histology. The epithelioid-only clusters share many of 
the features defining the corresponding clusters in the all-MPM solution (Fig. 5B). The 
survival analysis also paralleled the all-MPM solution, with cluster 1 having the best 
outcomes and cluster 4 having the worst (Fig. 5C). PARADIGM analysis of the epithelioid-
only subset confirmed upregulation of AURKA mRNA expression in the poor prognosis 
epithelioid-only cluster 4 (Fig. 5D), corroborating the results from the all-MPM analysis.
Finally, we sought to independently validate the clinical correlations of clusters identified in 
the TCGA epithelioid cases using mRNA expression profiles from two published studies: 
211 MPM analyzed by RNA-sequencing (5) and 52 MPM samples analyzed by mRNA 
expression microarrays (14). Specifically, we assigned each mRNA expression profile to one 
of the integrative clusters based on the rules derived from the TCGA mRNA dataset. For the 
larger validation cohort (henceforth referred to as Bueno), we restricted our analysis to 
epithelioid samples and used the epithelioid-only gene signature to cluster samples. We 
found that the epithelioid-only samples assigned to iCluster 1 (good prognosis) had 
significantly better survival, even after adjusting for age (P= 3.9×10−4; Fig. 5E and 
Supplementary Fig. S6). In the smaller cohort (referred to as Lopez-Rios), patient numbers 
were too small to split by histology. However, this analysis provided independent validation 
of the survival differences for the four all-MPM clusters (P=0.01; Supplementary Fig. S6). 
Taken together, these results suggest that the prognostically relevant molecular profiles 
defined by our analysis are robust and reproducible, and could be potentially used to 
improve risk stratification of patients with epithelioid MPM. The core mRNA gene lists are 
provided in Supplementary Table 4C-G which also include reduced classifiers based on 
methylation, lncRNA, miRNA, and a reduced classifier combining mRNA and methylation 
data to facilitate practical application of these data and independent validation of these 
clusters.
Analysis of noncoding RNAs in MPM
We next assessed two types of noncoding RNAs not extensively studied in MPM that may 
also represent a source of robust biomarkers: lncRNAs, which often show higher expression 
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specificity for cell type than coding genes, and miRNAs, which are relatively stable in 
biological fluids, so potentially suitable as noninvasive biomarkers.
In both the TCGA and Bueno (5) cohorts, lncRNAs returned four unsupervised consensus 
subtypes that were associated with 5-year survival (P=1.4×10−10 and P=1.1×10−3 
respectively). The TCGA lncRNA subtypes were highly concordant with iCluster 
(P=8×10−14) and PARADIGM (P=2×10−21) subtypes, and were associated with EMT scores 
(P=2.5×10−6) (Figs. 4A, 6A-E; Supplementary Table S5A.1). For both cohorts, lncRNAs 
that were differentially abundant between the good-prognosis subtype and other samples 
included those associated with cancer (e.g. H19, LINC00152, MEG3), or with MPM in 
particular: NEAT1 and SNHG8 (38), and GAS5 (39) (Fig. 6F,G; Supplementary Table S5B.
3–6). We noted that a number of lncRNAs distinguished the good-prognosis cluster in both 
TCGA and Bueno cohorts (Supplementary Table S5B.1–2,5–6).
Unsupervised clustering based on miRNA mature strands resolved five consensus subtypes 
in the TCGA cohort (Fig. 6H); these were associated with 5-year survival (P=7×10−4), 
iCluster (P=1×10−12) and PARADIGM (P=3×10−21) clusters, and associated with EMT 
scores (P=2×10−7) (Fig. 6H-K; Supplementary Table S5A.2). For the good-survival cases, 
the miRNA subtypes were strikingly concordant across multiple analysis platforms, and 
many cancer-associated miRNAs were differentially abundant in the good-survival cluster 
(Fig. 6L; Supplementary Table S5B.3–4). Taken together, these results suggest that lncRNAs 
and miRNAs may be important predictors of survival in MPM.
Epithelial-Mesenchymal Transition and VISTA expression
Because mRNA expression of EMT-associated genes was a key differentiating feature 
between prognostically distinct integrative clusters, we performed a detailed analysis of 
EMT in MPM using a previously published EMT-related mRNA signature (40). Increasing 
EMT scores significantly correlated with clusters defined by integrative algorithms (iCluster 
and PARADIGM), as well as with individual genomic features including miRNA, lncRNA, 
methylation, RPPA and overall gene expression (Fig 7A). Of all tumor types included in the 
TCGA pan-cancer analysis, MPM had the second-highest average EMT score (Fig. 7B) 
(after soft tissue sarcomas), consistent with previous reports that EMT is a frequent 
phenomenon in MPM (7,41).
While EMT score positively correlated with the mRNA expression of many immune 
regulatory genes, such as OX40L, TGFB1, CD276, OX40 and PD-L2 (p<0.001) (Fig. 7A 
and 7C), mRNA expression of VISTA (42), a negative immune checkpoint regulator 
primarily expressed on hematopoietic cells (43), was strongly inversely correlated with EMT 
score (Fig. 7C), and was expressed at levels higher than in any other TCGA tumor type 
analyzed (Fig. 7D). In the MPM cohort, VISTA mRNA levels were highest in the epithelioid 
subtype (Fig. 7C, E). Using Regulome Explorer (Supplementary Section 13), we found that 
VISTA mRNA expression was highly correlated with mesothelin mRNA expression 
(Spearman correlation=0.81; P=6.3×10−19), but not with mRNA expression of PD-1 or PD-
L1. Moreover, there was no significant correlation between overall mutation burden and 
VISTA expression levels (P=0.64).
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VISTA (V-domain Ig suppressor of T cell activation; also known as c10orf54, PD-1H, and 
B7-H5) is a member of the B7 family of negative checkpoint regulators, expressed on the 
surface of several immune cell types. It can function both as receptor and ligand (44). As a 
ligand, VISTA is present on the surface of antigen presenting cells (APC), and inhibits early-
stage T cell activation (45). The normal mesothelium has APC properties (46), which are 
retained upon malignant transformation (47,48). We thus performed immunohistochemical 
staining of two epithelioid TCGA MPM cases, as well as normal and reactive mesothelium 
(Supplementary Section 14), to define the cellular compartment expressing VISTA in MPM 
tumor samples. Remarkably, VISTA protein expression was not restricted to infiltrating 
immune cells, but was present in tumor cells in MPM, as well as in normal and reactive 
mesothelium (Fig 7F,G), suggesting that its expression in epithelioid MPM may reflect 
retention of APC properties in this more differentiated subset of MPM.
Discussion
Our comprehensive integrative analysis of 74 cases of MPM further defines a cancer driven 
primarily by inactivation of tumor suppressor genes. Indeed, we confirm the high frequency 
of BAP1 inactivation by mutation and copy number loss, as well as recurrent inactivating 
alterations in CDKN2A, NF2, TP53, LATS2 and SETD2. In addition to this landscape of 
known loss of function events, we have genomically characterized a novel molecular 
subtype of MPM accounting for approximately 3% of MPM in our datasets, defined by 
evidence of genomic near haploidization and recurrent TP53 and SETDB1 mutations, with a 
distinctive clinical phenotype showing female predominance and younger age at diagnosis. 
Our findings should facilitate systematic clinical studies of this subset to better define its 
survival and its association with asbestos exposure, which so far appears weak or unclear. 
Isolated cases with similar molecular profiles (genomic near-haploidization and SETDB1 
mutation) have been anecdotally reported (5,49), but had not, until now, been recognized as 
a distinct molecular subtype of MPM. The genomic data in our cases support a model in 
which early TP53 mutations are permissive for a loss of chromosomes to a near-haploid 
state, followed by genome reduplication and SETDB1 inactivation. As H3K9 methylation by 
SETDB1 is a repressive chromatin mark (50), it is tempting to speculate that inactivation of 
SETDB1 allows a general increase in transcription activity in a cancer cell that has sacrificed 
nearly half of its genome, presumably including several genes that are imprinted or 
otherwise monoallelically expressed. Why chromosomes 5 and 7 are spared from the LOH 
in these MPM remains mysterious – interestingly, the same two chromosomes have recently 
been shown to also retain heterozygosity in thyroid Hürthle cell carcinomas with evidence of 
genomic near haploidization (51). Overall, the identification of this novel subset of MPM 
highlights how, as the proportion of asbestos-related MPM plateaus and hopefully begins 
declining in Western countries, cases of possibly different etiology may become more 
apparent.
A better understanding of the determinants of aggressive behavior and predictors of poor 
clinical outcomes in MPM remains an unmet clinical need. To this end, integrative analyses 
with iCluster and PARADIGM revealed a set of molecular features that define MPM subsets 
with better and worse prognosis, and might point to candidate therapeutic targets. For 
instance, cases in the poor prognosis subset showed higher aurora kinase A mRNA 
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expression, consistent with prior studies (14,52). Treatment of MPM cell lines with an 
aurora kinase inhibitor leads to growth arrest (53), and several aurora kinase inhibitors are 
under investigation in MPM patients. AURKA mRNA expression could be used to help 
identify poor prognosis epithelioid MPM patients so that they could be directed towards 
experimental therapies early in their treatment course. It is presently unclear whether aurora 
kinase inhibitors will be active in MPM and the ongoing phase II study of alistertib 
(NCT02293005) includes all patients irrespective of molecular signature. While the value of 
targeting the AURKA pathway with currently available clinical compounds in MPM remains 
unknown, mRNA expression of AURKA is a prognostic marker that could be used in 
clinical practice to help stratify patients with epithelioid MPM.
Additionally, the poor prognosis group also exhibited upregulation of PI3K and mTOR 
signaling pathways. Preclinical studies have reported this finding, leading to clinical trials 
with a low response rate (2%) and no significant survival benefit in the salvage setting (54). 
These data suggest that combination therapies with mTOR inhibition may be necessary. Our 
analysis of epigenetic alterations revealed some associations between BAP1 status and DNA 
methylation (Supplementary Table S6). A recently established functional link between 
BAP1 and EZH2 (22) provided the rationale for the recently completed clinical trial of the 
EZH2 inhibitor tazemetostat in BAP1-null MPM (NCT028602). By contrast, no relevant 
findings resulted from our analysis of viral and microbial sequences (Supplementary Table 
S7). Finally, another genomically-driven potential vulnerability in MPM is very frequent 
CDKN2A deletion associated with co-deletion of MTAP, the latter recently shown to 
metabolically lead to impaired activity, and therefore sensitization to further inhibition, of 
the arginine methyltransferase PRMT5 (12,13), an inhibitor of which is currently being 
evaluated in a phase I trial (NCT02783300).
Harnessing current immunotherapy approaches to improve outcomes of patients with MPM 
is an area of intense clinical interest. While our study confirms that MPMs show a low tumor 
mutation burden and therefore may present a more challenging setting for immunotherapy, a 
remarkable and novel finding of the present study is that of strong expression of the immune 
checkpoint gene VISTA in epithelioid MPM, on the tumor cells themselves, unlike other 
cancer types where it is more often expressed on infiltrating reactive cells (42). VISTA is a 
member of the B7 family of negative checkpoint regulators that is expressed primarily on 
infiltrating tumor macrophages, and whose immune restraining effects on T cells may be 
similar to those of PD1 (43,55). However, unique structural features mean that VISTA can 
repress activation of T cells both as a ligand present on the surface of APC cells, and as a 
receptor on the surface of T cells (56). Because VISTA is expressed on MPM cells, and its 
mRNA expression levels do not correlate with overall mutation load, our results raise the 
possibility that VISTA expression may be restraining anti-tumor immune responses in a 
subset of MPM cases. As we find that non-neoplastic mesothelium also expresses VISTA 
protein, we speculate that VISTA expression in MPM is retained or possibly selected for by 
immune pressure. This is consistent with previous publications demonstrating that MPM is 
an ‘immunogenic’ tumor (57), including recent trials showing some responses to immune 
checkpoint blockade therapy (58,59). Indeed, VISTA has recently been reported as a 
possible compensatory immune inhibitory pathway in prostate cancers that fail to respond to 
ipilimumab (60). Our findings thus provide both a rationale and a candidate biomarker for 
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clinical trials of emerging anti-VISTA therapy (42,44) (NCT02812875) in epithelioid MPM. 
Taken together, our findings point to new lines of investigation into the biology of MPM 
with the potential to lead to new therapeutic strategies.
Materials and Methods
TCGA Project Management has collected necessary human subjects documentation to 
ensure the project complies with 45-CFR-46 (the “Common Rule”). The program has 
obtained documentation from every contributing clinical site to verify that IRB approval has 
been obtained to participate in TCGA. Such documented approval may include one or more 
of the following:
• An IRB-approved protocol with Informed Consent specific to TCGA or a 
substantially similar program. In the latter case, if the protocol was not TCGA-
specific, the clinical site PI provided a further finding from the IRB that the 
already-approved protocol is sufficient to participate in TCGA.
• A TCGA-specific IRB waiver has been granted.
• A TCGA-specific letter that the IRB considers one of the exemptions in 45-
CFR-46 applicable. The two most common exemptions cited were that the 
research falls under 46.102(f)(2) or 46.101(b)(4). Both exempt requirements for 
informed consent, because the received data and material do not contain directly 
identifiable private information.
• A TCGA-specific letter that the IRB does not consider the use of these data and 
materials to be human subjects research. This was most common for collections 
in which the donors were deceased.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Through a comprehensive integrated genomic study of 74 malignant pleural 
mesotheliomas (MPM), we provide a deeper understanding of histology-independent 
determinants of aggressive behavior, define a novel genomic subtype with TP53 and 
SETDB1 mutations and extensive loss of heterozygosity and discovered strong 
expression of the immune checkpoint gene VISTA in epithelioid MPM.
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Figure 1: Genomic and clinical features of the TCGA MPM cohort.
A: iCOMUT plot describing clinical and molecular features of the TCGA MPM cohort. 
Each column represents an individual case, whilst rows represent clinical and molecular 
features. Samples are grouped based on MPM histological type. Red arrowhead indicates the 
hypermutated case. Copy-number alterations are defined as follows: “Deletion” is a deep 
loss, possibly a homozygous deletion, “Loss” is a shallow loss (possibly heterozygous 
deletion), “Gain” indicates a low-level gain, and “Amplification” is a high-level 
amplification. Individual genes shown include significantly mutated genes and selected 
additional genes of interest. B: Observed mutational spectrum of the hypermutator case 
(TCGA-UD-AAC1) with 375 non-silent mutations. C: Observed mutational spectrum of the 
remaining other 73 MPM cases in the TCGA cohort (cohort average: 36 non-silent 
mutations/patient). D: Comparison of SMGs between the present study and that of Bueno et 
al, 2016.
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Figure 2: Supervised comparisons between BAP1-inactivated and wild-type MPM.
A: BAP1 inactivation by copy number loss or mutation across the cohort, along with 
mutations in 6 other genes (left). These genes were selected as those with more than 3 non-
silent mutated tumors. Large genes with more than 3kb coding regions (TTN, FAT4, MGA) 
are unlikely to be functional in cancer and were excluded. The bar plot (right) shows the 
Fisher-exact test p-values for mutual exclusivity and co-occurrence relative to BAP1. Only 
SETD2 and NF2 approach significant co-occurrence with BAP1 inactivation. The 1-tail 
Fisher p-values for co-occurrence and the Bejamini-Hochberg FDR’s are p=0.04, FDR=0.15 
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for SETD2 and p=0.05, FDR=0.15 for NF2. We detected MALAT1 (aka NEAT2) “RNA” 
mutations in 4 BAP1-inactivated samples, but this does not reach significance (p=0.05, 
FDR~0.27). B: Normalized BAP1 gene mRNA expression levels in the wild-type, 1 hit and 
2 hit subgroups. C: Box plot demonstrating a significantly lower frequency of arm-level 
losses in BAP1-inactivated tumors (BAP1 2) compared to wild-type (BAP1 0). D: Inferred 
transcription factor (TF) activities significantly associated with BAP1 inactivation 
(FDR<0.01). E: Volcano plot with mean inferred TF activity difference in BAP1 inactivated 
and BAP1 wild-type patients plotted on the x-axis, and false discovery rate (FDR)-adjusted 
significance from t-test plotted on the y-axis (–log10 scale). TFs significantly associated with 
BAP1 inactivation status (FDR<0.01) are colored in orange. F, G: Box plots with differential 
inferred activities of YY1 (F) and IRF8 (G), two biologically relevant transcription factors. 
The target genes on which inferences for YY1 (427 genes) and IRF8 (248 genes) activity 
were based are provided in Supplementary Table S2.
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Figure 3. MPM cases with genomic near-haploidization.
A: Whole exome sequencing-based LOH profiling with the FACETS algorithm revealed 
three MPM samples with genome-wide LOH. B: Allelic copy number plots of genome-wide 
LOH cases in the TCGA and Japanese ICGC cohorts. X-axis and Y-axis are the 
chromosome locations, and the ratio of an allelic copy number of tumor sample to that of 
matched normal control (lymphocyte), respectively. Red line shows the higher allele and 
blue line shows the lower allele. C: Near-haploid metaphase cell derived from the BWH 
genome-wide LOH cohort, stained by Giemsa, showing loss of one copy of all 
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chromosomes except 5, 7 and X. D: Allelic copy number plot of a representative TCGA case 
with biallelic inactivation of TP53 and monoallelic mutation of SETDB1, suggesting the 
latter occurred after the LOH and genome duplication events.
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Figure 4: Integrative analysis of 74 MPM.
A: Concordance between integrative (PARADIGM and iCluster) and platform-specific 
unsupervised clustering results. Clusters are color-coded and ranked based on survival (dark 
blue indicates best survival, whilst red and orange marks the worst surviving subgroup). B: 
Kaplan-Meier plot of the integrative subgroups reveals distinct outcomes. C: Cox regression 
analysis demonstrates significant associations of the molecular subtypes with patient 
survival, even upon adjusting for histology, age, and CDKN2A status. D: iCluster identified 
4 integrative subgroups with distinct BAP1 alteration (defined as mutation and/or copy 
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number alteration), TP53 mutation, CDKN2A status, copy number alteration, DNA 
methylation, mRNA, miRNA and lncRNA mRNA expression profiles. E: Comparison of 
Th2 cell immune gene mRNA expression signature across the four integrated clusters.
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Figure 5: Integrative analysis of epithelioid MPM.
A: Comparison of cluster assignments between the epithelioid-only and full cohort 
integrative analyses demonstrating good concordance, with only 7 cases being reassigned to 
another cluster. B: Integrative clustering analysis applied to cases with epithelioid histology. 
C: Kaplan-Meier plot of the epithelioid-only integrative subgroups. D: PATHMARK 
analysis revealed differentially active molecular pathways that define the poor prognosis 
epithelioid-only subgroup. E: Validation of the TCGA epithelioid subtypes in an 
Hmeljak et al. Page 27













independent cohort of 141 epithelioid MPM (Bueno et al.) confirming the protective effect 
of molecular features that define iCluster 1.
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Figure 6: Non-coding RNA Subtypes and differential abundance for lncRNAs and miRNAs in 
the TCGA and Bueno cohorts. a-g) LncRNA subtypes and differential abundance.
A: Top to bottom: Normalized abundance heatmap for a 4-subtype solution, then a silhouette 
width profile (Wcm) calculated from the consensus membership matrix; clinical and 
molecular covariates, with p-values from Fisher exact, Chi-square or Kruskal tests; and 
profiles of RNA-seq-based EMT scores and leukocyte fraction. B: Distribution of purity 
estimated by ABSOLUTE, with a Kruskal p-value. C: Distribution of RNA-seq-based EMT 
scores, with a Kruskal p-value. D: Kaplan-Meier plot for overall survival, with a log-rank p-
value. E: Kaplan-Meier plot for overall survival, with a log-rank p-value for a 4-subtype 
solution for the Bueno cohort. F,G: lncRNAs that were differentially abundant (SAM 2-class 
unpaired analysis, FDR < 0.05) between the better-survival lncRNA subtype and all other 
samples, for the TCGA cohort (F) and the Bueno cohort (G). The largest 15 positive and 15 
negative fold changes are shown; blue triangles mark lncRNAs that were in these gene sets 
in results for both cohorts. Text to the right of each barplot gives means-based fold changes, 
mean abundance in the target then the other samples, and the cytoband for the gene. See also 
Supplementary Table S5A. H-L) microRNA mature strand subtypes and differential 
abundance in the TCGA cohort. H: Top to bottom: Normalized abundance heatmap for a 
5-subtype solution, then a silhouette width profile (Wcm) calculated from the consensus 
membership matrix; clinical and molecular covariates, with p-values from Fisher exact, Chi-
square or Kruskal tests; and profiles of RNA-seq-based EMT scores and leukocyte fraction. 
I: Distribution of purity estimated by ABSOLUTE, with a Kruskal p-value. J: Distribution 
of RNA-seq-based EMT scores, with a Kruskal p-value. K: Kaplan-Meier plot for overall 
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survival, with a log-rank p-value. L: miRNA mature strands that were differentially 
abundant between the better-survival lncRNA subtype and all other samples, for the TCGA 
cohort. The largest 15 positive and 15 negative fold changes are shown. Text to the right of 
each barplot gives means-based fold changes, mean abundance in the target then the other 
samples, and the cytoband(s) for the mature strand. See also Supplementary Table S5B.
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Figure 7. MPM is enriched for both EMT and mRNA expression of immune targets.
A: Unsupervised analysis identifies correlations between EMT and multiple platforms. 
Tumors are ordered from left to right according to increasing EMT score. Numbered color 
bars indicate group assignments (clusters) from other data types. Statistically significant 
correlations are shown between EMT score and (starting at top) integrative multi-
dimensional analyses on both iCluster and PARADIGM platforms, along with mRNA, 
miRNA and lncRNA clusters, methylation status and consensus histology. Lower panels 
illustrate significant correlations between these clusters and selected miRNAs, proteins, 
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immune target genes. B: Spectra of EMT scores across different tumor types. Mesothelioma 
is the second most mesenchymal cancer type after sarcoma in 31 tumor types analyzed. 
Despite most MPM tumors having undergone EMT, a broad range of EMT scores were 
observed across mesothelioma cases, which corresponded to a large extent with histologic 
subtype. C: Waterfall plot illustrating the correlation between EMT and immune target 
genes. D: Plot highlighting VISTA gene mRNA expression, which is highest in MPM, 
across all TCGA tumor types. E: Box plot indicating VISTA mRNA expression levels in 
individual histological types of the TCGA MPM cohort. The highest mRNA expression 
levels were observed in the epithelioid subtype (Wilcoxon rank-sum, p=2e-7), whilst 
sarcomatoid MPM had the lowest mRNA expression (p=0.017). Red arrows indicate two 
epithelioid cases that were examined by immunohistochemistry, TCGA-SC-A6LQ-01 (1) 
and TCGA-SC-A6LM-01 (2). F: Immunohistochemical staining for VISTA (Rabbit 
monoclonal anti-VISTA antibody, clone D1L2G, 0.1 μg/mL, Cell Signaling Technology, 
Danvers, MA, USA) in normal mesothelial lining from pleura (*) and benign pleuritis with 
reactive mesothelial proliferation (**), and 2 TCGA MPM cases, TCGA-SC-A6LQ-01 (1) 
and TCGA-SC-A6LM-01 (2); images captured at 100x magnification. These results confirm 
high protein expression of VISTA on tumor cells in epithelioid MPM. G: VISTA 
immunohistochemistry. VISTA protein is expressed both in tumor cells (red arrows) and in 
infiltrating inflammatory cells (black arrows) in the epithelioid MPM case TCGA-SC-
A6LQ-01. Image captured at 200x magnification.
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